PIRENOXINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H8N2O5
Molecular Weight	308.2451
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)c1cc(O)c2c3nc4ccccc4oc3cc(=O)c2n1

InChI

InChIKey=OKPNYGAWTYOBFZ-UHFFFAOYSA-N

InChI=1S/C16H8N2O5/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12/h1-6H,(H,18,19)(H,21,22)

HIDE SMILES / InChI

Molecular Formula	C16H8N2O5
Molecular Weight	308.2451
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160
Curator's Comment: description was created based on several sources, including, http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9

Pirenoxine is an anti-cataract agent which is used in many asian countries under the name Catalin. Although its efficacy is not proved scientifically, the drug may play an important role in cataract prevention. It is supposed that the anti-cataract effect of pirenoxine results from inhibition of sulfhydryl combination of quinoid substances with lens proteins and the inhibition leads to the maintenance of lens transparency.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
maintenance of lens transparency 2 Target ID: GO:0036438 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Senile cataract 2 Sources: http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9	Preventing		Approved 8583	CATALIN Approved Use Early stage of senile cataract.

PubMed

Title	Date	PubMed
[Efficacy of catalin eyed drops in age-related cataract agents].	2010-07-22	20645574
Why are physicians not persuaded by scientific evidence? A grounded theory interview study.	2006-07-27	16872522
Pirenoxine prevents oxidative effects of argon fluoride excimer laser irradiation in rabbit corneas: biochemical, histological and cytofluorimetric evaluations.	2005-01-14	15629247
Contact dermatitis due to pirfenoxone.	2004-06	15274732
[Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract].	2004	15787181
Antioxidant protection in cultured corneal cells and whole corneas submitted to UV-B exposure.	2003-10-15	14705640

Patents

Sample Use Guides

In Vivo Use Guide

Dissolve the granules (0.75 mg) in 15 ml of the vehicle just before use and instill 1-2 drops of the solution, 3-5 times a day

Route of Administration: Other

In Vitro Use Guide

Pirenoxine (1,000 uM) decreased UVC-induced turbidity formation compared to controls after 4 h of UVC exposure. The absolute gamma-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of catalin equivalent to 1-100 uM of the drug in a concentration-dependent manner. Pirenoxine at 0.03, 0.1, and 0.3 uM significantly delayed 10 mM selenite- and calcium-induced turbidity formation compared to controls on days 0-4.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:29:17 GMT 2025` Edited by `admin` on `Mon Mar 31 18:29:17 GMT 2025`
Record UNII	27L0EP6IZK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIRENOXINE

Official Name

English

CATALIN-K

Preferred Name

English

pirenoxine [INN]

Common Name

English

PIRENOXINE [JAN]

Common Name

English

PIRENOXINE [MI]

Common Name

English

Pirenoxine [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QS01XA91